Laurence Klotz, MD, FRCSC, CM

Active Surveillance for Prostate Cancer: How to Do It Right

May 16, 2017

In this review of active surveillance for favorable-risk prostate cancer, we will discuss the rationality of this approach, the biological evidence for employing active surveillance in Gleason pattern 3 and 4 prostate cancer, patient selection for active surveillance, clinical trial data on active surveillance, and the role of prostate cancer biomarkers and imaging studies for clinical decision making in patients with low-risk disease.

Laurence Klotz on the Controversy Surrounding Screening for Prostate Cancer

August 15, 2016

Laurence Klotz, MD, FRCSC, CM

In this interview we discuss PSA screening for prostate cancer, the compromised results of the PLCO trial, and more.

Low-Risk and Very-Low-Risk Prostate Cancer: Is There a Role for Focal Therapy in the Era of Active Surveillance? Yes, the Two Approaches Complement Each Other

November 15, 2014

Investigators and physicians caring for the spectrum of prostate cancer should have a targeted treatment option available for patients who would benefit by it.

Active Surveillance Not Only Reduces Morbidity, It Saves Lives

June 15, 2013

Laurence Klotz, MD, FRCSC, CM

The concept of active surveillance is based on the observation that Gleason 6 (pattern 3) prostate cancer is an indolent condition that poses little or no threat to the patient’s life. Conservative management is thus appropriate for these patients.

Commentary (Klotz): Management of Asymptomatic Rising PSA After Prostatectomy or Radiation Therapy

April 1, 1997

Laurence Klotz, MD, FRCSC, CM

This article addresses an increasingly common dilemma: the finding of a rising prostate-specific antigen (PSA) level in an asymptomatic patient following radical surgery or radiation therapy for prostate cancer. The incidence of prostate cancer has skyrocketed, and the number of men being treated with radiation or radical prosta-tectomy has similarly increased. The most common basis for the initial diagnosis of prostate cancer is an elevated PSA. For the patient who is already sensitized to PSA as a diagnostic marker, it is extremely distressing to learn that his PSA is rising following radical treatment. This is particularly true for the patient who has experienced a treatment-related adverse effect on quality of life. For the treating physician, this all-too common scenario is disappointing and even guilt-laden.